Spyre Therapeutics, Inc. (SYRE)
85.69
+5.79
(+7.25%)
USD |
NASDAQ |
Oct 09, 16:00
85.71
+0.02
(+0.02%)
Pre-Market: 20:00
Spyre Therapeutics Free Cash Flow : -209.47M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -209.47M |
| March 31, 2026 | -185.87M |
| December 31, 2025 | -169.41M |
| September 30, 2025 | -162.30M |
| June 30, 2025 | -154.68M |
| March 31, 2025 | -170.36M |
| December 31, 2024 | -157.82M |
| September 30, 2024 | -151.32M |
| June 30, 2024 | -156.42M |
| March 31, 2024 | -110.82M |
| December 31, 2023 | -99.91M |
| September 30, 2023 | -87.01M |
| June 30, 2023 | -67.49M |
| March 31, 2023 | -71.52M |
| December 31, 2022 | -80.18M |
| September 30, 2022 | -81.31M |
| June 30, 2022 | -83.33M |
| March 31, 2022 | -60.61M |
| December 31, 2021 | -54.29M |
| September 30, 2021 | -53.15M |
| June 30, 2021 | -54.16M |
| March 31, 2021 | -76.95M |
| Date | Value |
|---|---|
| December 31, 2020 | -80.06M |
| September 30, 2020 | -79.39M |
| June 30, 2020 | -78.64M |
| March 31, 2020 | -74.34M |
| December 31, 2019 | -67.18M |
| September 30, 2019 | -57.12M |
| June 30, 2019 | -48.37M |
| March 31, 2019 | -41.01M |
| December 31, 2018 | -32.62M |
| September 30, 2018 | -31.28M |
| June 30, 2018 | -30.15M |
| March 31, 2018 | -27.06M |
| December 31, 2017 | -25.23M |
| September 30, 2017 | -23.65M |
| June 30, 2017 | -22.03M |
| March 31, 2017 | -20.76M |
| December 31, 2016 | -19.05M |
| September 30, 2016 | -15.45M |
| June 30, 2016 | -13.53M |
| March 31, 2016 | -12.69M |
| December 31, 2015 | -11.19M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| AbbVie, Inc. | 18.21B |
| Incyte Corp. | 1.890B |
| SELLAS Life Sciences Group, Inc. | -28.42M |
| Relay Therapeutics, Inc. | -212.20M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -70.16M |
| Cash from Investing (Quarterly) | -297.90M |
| Cash from Financing (Quarterly) | 432.89M |
| Free Cash Flow Per Share (Quarterly) | -0.828 |
| Free Cash Flow to Equity (Quarterly) | -70.16M |
| Free Cash Flow to Firm (Quarterly) | -70.16M |
| Free Cash Flow Yield | -3.27% |